Are the days of missed or delayed diagnosis of gout over?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. A comprehensive analysis of trends in the burden of gout in China and globally from 1990 to 2021.Scientific reports · 2025
   Article
2. Prescribing cascades of antigout medications from thiazide diuretics in gout-naïve hypertensive adults receiving first-line pharmacological management.Scientific reports · 2024
   Article
3. Epidemiology of gout - Global burden of disease research from 1990 to 2019 and future trend predictions.Therapeutic advances in endocrinology and metabolism · 2024
   Article
4. Trend dynamics of gout prevalence among the Chinese population, 1990-2019: A joinpoint and age-period-cohort analysis.Frontiers in public health · 2022
   Article

Corrections and comments

• Comment on
  2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as